Strategy / Newly Independent Sandoz Predicts $3 Billion in Biosimilars Sales over Next 5 Years
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…